Abstract
We report the findings of a study examining the relationship between in vitro daptomycin-rifampin synergy and the therapeutic outcome of 12 patients with complex deep methicillin-resistant Staphylococcus aureus (MRSA) infections treated for prolonged periods with this combination. Checkerboard synergy was found in nine cases and was 100% predictive of therapeutic success; absence of synergy was found in three cases, two of which were therapeutic failures (P = 0.045). No relationship was observed between synergy and outcome by time-kill assessment. Checkerboard synergy may predict clinical response to daptomycin plus rifampin for complex invasive MRSA infections requiring prolonged treatment. Copyright © 2013, American Society for Microbiology.
Cite
CITATION STYLE
Rose, W. E., Berti, A. D., Hatch, J. B., & Maki, D. G. (2013). Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections. Antimicrobial Agents and Chemotherapy, 57(7), 3450–3452. https://doi.org/10.1128/AAC.00325-12
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.